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Abstract
Introduction: HER2 status assessment became a mandatory test assay in breast cancer, giving prognostic and predictive
information including eligibility for adjuvant anti-HER2 therapy. Precise and reliable assessment of HER2 status is therefore
of utmost importance. In this study we analyzed breast cancer samples by a novel technology for concomitant detection of
the HER2 protein and gene copy number.
Methods: Tissue microarrays containing 589 invasive breast cancer samples were analyzed with a double
immunohistochemistry (IHC) and silver labeled in situ hybridization (SISH) assay simultaneously detecting HER2 protein
and gene copy number in the same tumor cells. This bright-field assay was analyzed using scores according to the modified
ASCO guidelines and the results were correlated with patient prognosis.
Results: Overall concordance rate between protein expression and the presence of gene amplification was 98%. Fifty-seven
of 60 tumors (95%) with IHC score 3+, 6 of 10 tumors with IHC score 2+ (60%) and only 3 of 519 tumors (0.6%) with IHC
score 0/1+ were amplified by SISH. Patients with gene amplification despite IHC score 0/1+ had a tendency for worse overall
survival (p = 0.088, reaching nearly statistical significance) compared to IHC score 0/1+ without amplification. In contrast,
there was no difference in overall survival in IHC score 3+/2+ tumors with and without gene amplification.
Conclusions: The novel double IHC and SISH assay for HER2 is efficient in the identification of breast cancer with discordant
HER2 protein and HER2 gene status, especially for the prognostically relevant groups of HER2 protein negative tumors with
HER2 amplification and HER2 protein positive tumors without HER2 amplification. Breast cancer without HER2 amplification
among IHC score 2+/3+ tumors (10% in our cohort) suggests that other mechanisms than gene amplification contribute to
protein overexpression in these cells.
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Introduction
Determination of HER2 status in breast cancer is important in
the diagnosis of breast breast cancer by pathologists [1–6].
Accurate detection of the HER2 protein and/or gene amplifica-
tion is of enormous importance, as adjuvant or neoadjuvant
therapy decisions, made on the assays, all rely on the scores that
are given by these tests [4,5,7].
The ASCO guidelines approved several test assays for the
HER2 status assessment including immunohistochemistry (IHC)
and/or in situ hybridization (ISH) technics with different
visualization methods as fluorescence (FISH), silver (SISH) or
chromogenic (CISH) labeled probes [2,5,6]. These tests are
conducted in a single way, either immunohistochemistry comple-
mented with ISH technology or the ISH technology alone. In the
literature, a good correlation could be found between standardized
IHC and ISH technology, justifying the use of only one of these
technologies in the routine diagnostic service. Furthermore,
correlation of test results obtained by IHC and/or ISH tests,
was proven to correlate with therapy response and with overall
survival in several previous studies, confirming the prognostic and
predictive value of these test assays [8–11]. A novel bright-field
assay for concomitant detection of HER2 gene status and protein
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expression on one tissue section has been described by Tubbs et al.
[12]. This assay allows the identification of tumor cells with
discordant HER2 results, e.g. HER2 protein overexpression
without evidence for HER2 gene amplification.
In this study, we addressed the question whether such tumors
with discordant results by IHC and SISH represent prognostically
relevant subgroups. We are not aware of any previous studies,
correlating results of this bright-field assay with patient prognosis
[12,13].
Materials and Methods
Patients’ cohort
Tissue microarrays (TMAs) containing eligible 652 samples
from breast cancer patients were selected for this study. Eligibility
was decided upon availability of sufficient tumor tissues in the
paraffin blocks. The TMAs were constructed previously as
described [14]. Clinical data, at least five years follow-up and
complete histopathological parameter including hormone receptor
status (ER, PR), histological grading were available to all patients,
tumor stage and the presence of local or distant recurrence were
available for most of the patients.
The cohort was composed of 318 primary breast cancer (49%),
26 local recurrences (4%), 258 axillary lymph node metastases
(39%) and 50 visceral metastases (8%). For the TMA analysis there
were 589 of 652 interpretable samples available.
Histologically, there were 280 invasive ductal (88%), 35 invasive
lobular carcinomas (11%) and 5 special types (1%). Grading was
assessed by applying the modified Bloom and Richardson grading
system after Ellis and Elston on the primary tumors and on most of
the metastatic and recurring lesions [15], 89 cases were Grade 1
(13%), 318 cases were Grade 2 (49%) and 213 cases Grade 3
(33%), in 32 cases (5%) grading was not available in the metastastic
lesions. The retrospective study on human tissue samples was
approved by the Cantonal Ethical Committee of Zurich (KEK-
2012-553). Informed consent was not necessary, as the ethical
approval covered the ethical issues of the retrospective study and
the samples were completely anonymized and de-identified prior
to the study.
Details of clinico-pathological parameters are depicted in
Table 1.
Concomitant detection of HER2 protein expression and
HER2 gene copy number
For the simultaneous detection of the HER2 protein and HER2
gene copy number, we used a previously described protocol by
Tubbs et al and Downs-Kelly et al. [12,13]. The idea of this
technology is a metallographic based procedure which comprises
an enzymatic interaction between peroxidase or other enzymes
and silver or other metal associated substrates. These interactions
result in the deposition of the given metallic substrates at the
corresponding protein site or gene locus within the cell. The best
results were achieved by the combination of peroxidase and silver
linked substrates [12,13]. The procedure was carried out as
follows: Unstained slides of 4 micrometer thickness were prepared
from the paraffin block of the TMAs, one of them stained for
routine hematoxylin & eosin to confirm the presence of sufficient
amount of invasive tumor cells in the spots. One unstained slide
underwent subsequent immunohistochemical treatment with the
CB11 clone of the HER2 protein combined with metallic silver
deposition of EnzMet GenePro completed with alkaline phosphate
and fast red K substance for visualization according to the
manufacture’s recommendations (all reagents were purchased by
Ventana Tucson, AZ, USA). Additionally, the Inform HER2 dual
DNA Probe Cocktail with the UltraView SISH Detection Kit
(HER2 locus) and UltraView Red ISH DIG Detection Kit
(CEP17 locus) were done on the same tissue micro arrays.
Reactions mentioned above in both detection systems (except the
hybridization step) were carried out on the automatic Benchmark
system (Ventana, Tucson, AZ, USA). The hybridization step
(containing the HER2 and CEP17 gene locus on chromosome 17)
was carried out manually according to the instruction of the
EnzMettrade mark, Nanoprobes (Yaphank, NY, USA) and on the
automatic Benchmark ULTRA system (Ventana, Tucson, AZ,
USA). The HER2 protein was visualized as a purple-red (EnzMet)
or DAB brown (Inform) membranous stain, the gene loci (HER2)
as confluent black aggregates or singular black spots, the CEP17
region with red spots or aggregates [12,13].
Scoring of HER2 protein and HER2 gene copy number
The simultaneous detection of the HER2 protein and HER2
gene was originally scored according to the 2008 guidelines on
HER2 scoring in breast cancer [6]. Retrospectively, the TMA
spots were evaluated again (done by Z.V.) using the modified 2013
ASCO/CAP guidelines[5].
SISH HER2 signals were scored as follows: the number of
signal copies and the ratios (HER2/CEP17) were calculated, gene
copies (.6) or cluster formations (small clusters ,6 copies, larger
clusters ,12 copies) were defined as amplified. Similarly, a ratio
.2.2 was set as amplified status; a ratio ,1.8 was negative, and a
ratio of 1.8–2.2 was referred to as unequivocal (according the 2008
guidelines) and using ratio .2 and . or equal to 6 HER2 gene
copies (in .10% of the tumor cells) for a positive status (according
to 2013 guidelines).
HER2 protein expression was scored as follows: 0 (no
staining), 1+ (weak and incomplete membrane staining), 2+
(strong, complete membrane staining in less than 30% of the
invasive tumor cells or weak/moderate heterogeneous complete
staining in more than 10% of the invasive tumor cells) or 3+
(strong complete homogenous membrane staining in more than
30% of the invasive tumor cells). According to the 2013 ASCO/
CAP guidelines, the required percentage (10%) for score 3+ and
2+ were used for the re-evaluation of the results based on the 2008
guidelines (Fig. 1).
Statistical analysis
SPSS 15.0 software was used for statistical comparisons (SPSS,
Inc., Chicago, IL, USA). Categorical data were analyzed using
Chi- Square test. Spearman log rank, Pearson, Breslow and
Tarone Ware correlation were used to correlate HER2 protein
expression scores and HER2 gene copy number with and clinic-
pathological parameters (stage and grade, hormone receptor
status) and overall survival. Non-parametrical tests as Kendall Tau
and Spearman rho were used to test correlation between overall
survival and HER2 scores with IHC and SISH.
Results
Concordance of IHC and SISH
There were 589 interpretable spots containing sufficient amount
of invasive carcinomas on the TMAs. Sixty of 589 cases were score
3+ by IHC (10%). Fifty-seven of 60 IHC score 3+ cases showed
also amplification by SISH (95%). 519 of 589 cases were negative
(score 0/1+) by IHC (88%). 3 of 519 IHC negative breast cancers
(score 0/1+) showed amplification by SISH (0.6%). Ten of 589
samples were score 2+ by immunohistochemistry (5%), 6 of these
cases displayed amplification by SISH (60%). One of the IHC
HER2 Protein and Gene Alterations by IHC and SISH in Breast Cancer
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score 3+ cases showed polysomy of both CEP 17 and HER2 gene
(,1%) (Table 2).
Correlation of IHC and SISH scores with overall survival
There was a significantly shorter overall survival among patients
whose tumors were either amplified by SISH (p= 0.002) or were
IHC score 2+ or 3+ (p = 0.006), when these two parameters were
analyzed separately (Fig 2. and Fig 3).
When combining IHC and SISH scores, there was as tendency
to shortened overall survival in patients with IHC score 1+ with
simultaneous gene amplification, when compared to IHC score 0/
1+ tumors without gene amplification (p = 0.088, nearly reaching
statistical significance), (Fig. 4). No significant difference in 5 year
overall survival of IHC score 3+/2+ tumors without gene
amplification was seen in this cohort, when results were compared
to IHC score 3+/2+ with concomitant gene amplification (Fig. 5
and Fig. 6). Amplified cases with IHC score 1+ had a similar
overall survival as IHC score 3+/2+ cases with simultaneous gene
amplification by SISH (Fig. 7).
Correlation of IHC HER2 and SISH HER2 scores with
clinico-pathological parameters
IHC HER2 scores significantly correlated with hormone
receptor status (p = 0.001) and histological grading (p,0.001)
and lacked correlation to pathological tumor stage, nodal status or
to the presence of distant metastases.
SISH HER2 scores also showed a significant correlation to
hormone receptor status (p = 0.002) and to histological grading
(p,0.001), but not to tumor stadium, nodal status or to distant
metastases.
Concordance of double IHC/SISH HER2 testing to original
HER2 status
Original HER2 status was available in 310 primary tumors
performed by IHC and FISH technology. There were 6 of 310
(1.9%) discrepant cases with IHC and 7 of 310 (2.2%) discrepant
cases with FISH as compared to double IHC/SISH HER2 testing.
Table 1. Clinico-pathological characteristics of samples in the tissue micro arrays.
n %
Type of tissue samples (n =652)
Primary breast cancer 318 49%
Recurrent lesion 26 4%
Axillary lymph node metastasis 258 39%
Visceral metastasis 50 8%
Histological grade (all lesions)
G1 89 13%
G2 318 49%
G3 213 33%
Missing 32 5%
pT stadium (all lesions)
pT1 182 24%
pT2 301 40%
pT3 41 6%
pT4 101 13%
missing 128 17%
pN stadium (all lesions)
pN0 39 6%
pN1 429 62%
missing 220 32%
ER/PR status (primary tumor)
Positive 254 80%
Negative 64 20%
HER2 status (primary tumor)
positive 28 9%
negative 290 91%
Histological type (primary tumor)
Invasive ductal 280 88%
Invasive lobular 35 11%
Other type 3 1%
doi:10.1371/journal.pone.0105961.t001
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Discussion
We analyzed HER2 status in a cohort of invasive breast cancers
using a double IHC/SISH assay, enabling the simultaneous
detection of the HER2 protein expression and the HER2 gene
copy number. Importantly, the simultaneous detection of HER2
protein and HER2 gene copy number facilitates the identification
of relevant prognostic subgroups with poor prognosis especially in
the IHC score 0/1+ group with amplification and in the IHC
score 3+/2+ group without gene amplification.
The novel technology of bright field protein and gene detection
assay was developed and described in 2004 by Tubbs et al [12,13].
This innovative approach for simultaneous detection of protein
overexpression and gene copy number provides several advantages
over established FISH and IHC based technologies [12,13]. FISH
is a precise yet robust analysis, which needs thorough technical
expertise both in localizing and interpreting the signals [12,13].
The bright field in situ hybridization technology, originally named
as EnzMet, today known as SISH (silver enhanced in situ
hybridization) is an enzyme metallographic probe labeling,
resulting in silver coloration of the hybridized gene sequence.
This provides a higher sensitivity and higher resolution of the
amplified and non-amplified gene regions, which can be visualized
and analyzed on the light microscope [12,13]. The advantage of a
permanent result and the possibility of bright-field microscopy
make SISH an attractive alternative to FISH. We have recently
demonstrated a high concordance of SISH and FISH results in the
detection of EGFR copy number alterations in lung cancer
samples and we have provided data that SISH is an accurate
method for the evaluation of the Her2 gene amplification status in
cytologic breast cancer specimens, particularly in metastatic breast
cancer lesions [16] [17].
In our TMA-based study, we demonstrate an excellent
correlation between IHC score 3+ and gene amplification by
SISH using a dual probe for IHC and SISH. Concordance
between IHC and ISH technologies in HER2 status assessment in
breast cancer has been the subject of several previous studies
[3,6,18,19]. These studies confirmed a realistic concordance
Figure 1. Breast cancer tumor samples with different HER2 results by double HER2 IHC/SISH. Red spots correspond to the centromere
17, black spots to the HER2 gene. A) Sample with IHC score 3+ with simultaneous amplification of the HER2 gene by SISH. B) Another sample with IHC
score 0/1+ with simultaneous amplification of the HER2 gene by SISH. C) Illustration of a case with IHC score 3+ without simultaneous amplification of
the HER2 gene by SISH. D) Another case with IHC score 1+ without simultaneous amplification of the HER2 gene by SISH.
doi:10.1371/journal.pone.0105961.g001
Table 2. HER2 status results by double immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) on the tissue
micros arrays (n = 589 interpretable spots).
SISH Total
IHC Non amplified amplified polysomy
Score 0 and 1+ 516 3 0 519
Score 2+ 4 6 0 10
Score 3+ 2 57 1 60
Total 522 66 1 589
doi:10.1371/journal.pone.0105961.t002
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Figure 2. HER2 status by IHC alone. Statistical analysis with Kaplan Meier curves. IHC 0/1+, 2+ and 3+ scores significantly stratify patients
in overall survival. Patients with IHC score 2+ and 3+ have significantly shortened overall survival.
doi:10.1371/journal.pone.0105961.g002
Figure 3. HER2 status by SISH. Statistical analysis with Kaplan Meier curves. Positive HER2 amplification status is associated with
significantly shortened overall survival.
doi:10.1371/journal.pone.0105961.g003
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between IHC and SISH technology, especially in settings where
ISH is applied as reflex testing in IHC score 2+ cases. In order to
keep necessary acceptable quality standards, the ASCO/CAP
guidelines have set a minimum of 95% concordance between IHC
and ISH technologies, when both methods are used [6,20]. The
need for standardized methodologies in HER2 testing, including
not only internal quality assurance procedures but also test
validation, sufficient fixation time, proper training of involved
technical and medical staff persons, have been added to several
guidelines [7,18,20–25]. Although fixation time might be different
Figure 4. Stratification of IHC score 0/1+ tumors and amplification status by SISH to overall survival. There is a tendency to shorter
overall survival in HER2 amplified IHC score 0/1+ cases (Kaplan Meier curves).
doi:10.1371/journal.pone.0105961.g004
Figure 5. Correlation of IHC score 2+ scores and amplification status by SISH to overall survival. Amplification status in patients with IHC
score 2+ had no impact on overall survival (Kaplan Meier curves).
doi:10.1371/journal.pone.0105961.g005
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Figure 6. Correlation of HER2 amplification status by SISH in IHC score 3+ tumors with overall survival. Overall survival of IHC score 3+
tumors was independent from amplification status by SISH in this cohort (Kaplan Meier curves).
doi:10.1371/journal.pone.0105961.g006
Figure 7. Overall survival of HER2 amplified tumors by SISH. HER2 SISH amplified cases had a similar overall survival irrespectively from HER2
IHC scores.
doi:10.1371/journal.pone.0105961.g007
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in samples in a TMA cohort, this was obviously not significantly
affected by analytic laboratory and interpretational issues.
Here, we demonstrate that the novel bright-field ISH assay
enables improved diagnosis in borderline breast cancer cases.
Simultaneous assessment of HER2 status by IHC and SISH shows
a significant correlation to overall survival. The use of different
ISH assay for the assessment of the HER2 status was assessed in
several previous works [2,18,26–31]. These works demonstrate
that FISH based HER2 assays and the bright field ISH
technologies (as silver or chromogenic enhanced technologies)
provide highly concordant information on HER2 status. These
alternative ISH tests as CISH or SISH have shown a good to
excellent correlation between the tests themselves, and IHC score
3+ and ISH amplified cases, varying from 89% to 98% [2,18,26–
31]. According to our knowledge, only one of these studies
examined simultaneously the HER2 protein expression by
performing IHC prior to SISH on the same slide in a cohort of
gastric and breast cancer cases [31].
Our study confirms existing data that IHC score 2+/3+ tumors
as well as tumors with HER2 gene amplification represent
prognostically poor subgroups with shortened overall survival
[7,20], but our results are of importance for recommendations
using either FISH or IHC alone. Given the low rate of IHC score
0/1+ cases, many breast cancer centers recommend FISH as a
primary and only test assay for HER2 analysis (REF). We have
recently reported that HER2 positivity rate remained stable by
FISH-technology, but showed a significant variation by IHC in a
single institution over 12 years [32]. This can be considered as a
further argument for a FISH alone test approach. However, our
results obtained with the novel double immunohistochemistry
(IHC) and silver labeled in situ hybridization (SISH) assay
demonstrated that patients with IHC score 3+/2+ with and
without amplification have the same survival. The FISH only test
approach would have missed patients with IHC score 3+/2+
without amplification with the consequence that these patients
would have not received Trastuzumab therapy.
The underlying mechanism of protein overexpression in breast
carcinomas is preferential amplification or polysomy of the HER2
gene. This amplification can vary in size, especially in IHC scores
3+ cases [7,20]. It is well documented that IHC score 3+ cases may
lack gene amplification. This phenomenon is reported in up to
20% of tested cases and can be due to pre-analytical and
interpretational factors including false-negative polysomy [3–
5,7,19,33]. In some instances, protein overexpression occurs as
the result of true aneuploidy with numerical changes of the whole
chromosome 17, but this phenomenon is preferentially seen in
HER2 IHC scores 1+/2+ tumors. Both mechanisms can occur
also concomitantly within the same tumor, potentially yielding
further interpretational issues. The double immunohistochemistry
and silver labeled in situ technology is able to separate high level
amplifications and/or polysomy of chromosome 17 as relevant
mechanisms for HER2 overexpression in tumor cells. In our
cohort, we found a very low incidence of real polysomy, only one
of 589 cases showed polysomy with SISH and displayed IHC score
3+, This observation is indeed consistent with current recommen-
dations as to precise handling and interpretation of polysomy in
HER2 status [1,4,5].
As to the real frequency of IHC score/1+ cases having
simultaneous amplification, the literature is inconsistent, mostly
due to the fact, that IHC score 0/1+ cases do not need to undergo
obligatory reflex testing with an ISH technology [6,19,23].
Nevertheless, this phenomenon can be seen in up to 10% of
breast cancer cases [23,26–28,30,34]. It is to assume, that pre-
analytical factors as poor fixation or laboratory procedure errors
contribute to a false-negative or weak signal in IHC and can
explain why gene amplification do occur in IHC score 0/1+ cases
[7,23]. The prognostic/predictive role of IHC score 0/1+ with
amplification has not been studied extensively [8,10,11]. The
recently closed HERA trial could show that neither IHC staining
intensity nor the ratio of FISH testing had significant impact on
response to Trastuzumab therapy in HER2 positive disease.
Results of conflicting outcome data raise the role of possible pre-
analytical inconsistencies in HER2 status assessment as well [8,11].
On the other hand, the N9831 trial, provided lack of evidence on
benefit on Trastuzumab and/or on survival benefit in HER2
negative (IHC and/or FISH) breast cancer [10]. An earlier paper
of Mass et al. found a benefit for Trastuzumab therapy only in
FISH positive tumors [9]. In our cohort, we could identify three
patients with IHC score 0/1+ with simultaneous gene amplifica-
tion by SISH. Even though this is a small number, these three
patients had a similar survival curve as patients with IHC score 3+
and amplification. Interestingly, IHC score 2+ cases in our cohort
displayed a shortened survival independently from the presence of
gene amplification. The relatively low IHC score 2+ rate with a
high concomitant amplification rate in our cohort is most likely
explainable due to the unbalanced study population in the tissue
micro-arrays.
Several problematic topics in routine HER2 testing prompted
the revision of the 2007 ASCO/CAP guidelines on HER2
diagnostic guidelines. Diversities in the interpretation of chromo-
some 17 aneuosomy and of HER2/CEP17 ratios may lead to false
negative and false positive HER2 status, having an immediate
impact on therapy options for the given patient. Tumor
heterogeneity, biological characteristics and pre-analytic issues
have been also shown to influence accuracy in HER2 status
assessment [5] [32]. As addressed also in our study, the
identification of prognostically relevant subgroups in breast cancer
is of utmost importance, which requires established precise
technologies and interpretation.
Our cohort contained also samples from metastases but not
from the primary lesions. In metastatic lesions, there was only one
case with discordant HER2 protein and HER2 gene status.
Concordance in HER2 status between primary tumors and
metastastic sites was the subject of several previous studies,
confirming a high consistency in cases with only one metastastic
site [7,20]. At the same time, changes in HER2 status were
reported in metastatic breast cancer patients with multiple
metastatic sites and has also been observed in breast cancer
samples after adjuvant or neoadjuvant chemotherapy [7,20].
Conclusions
We provide data that HER2 gene amplification independently
from HER2 protein expression in IHC score 0/1+ cases correlates
with tendency to poorer overall survival. Importantly, our data
suggest that the double immunohistochemistry and silver labeled
in situ hybridization assay identifies a prognostically relevant IHC
2+/3+ breast subgroup without HER2 amplification, which
cannot be detected using a FISH alone approach.
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